TAMBOCOR
LOE ApproachingNDAORALTABLET
Approved
Oct 1985
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TAMBOCOR (flecainide acetate) is an oral antiarrhythmic agent approved in 1985 for the treatment of cardiac arrhythmias. The exact mechanism of action and specific indications are not detailed in available data, but it is a small-molecule tablet indicated for rhythm management in patients with arrhythmia disorders.
LOE Approaching
This product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating a contracting commercial footprint and likely consolidation of the brand team.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal active hiring for TAMBOCOR-specific roles; this product does not represent a growth career opportunity. Working on TAMBOCOR is typically a sustainment or legacy brand assignment, best suited for professionals managing mature portfolios or preparing for transition roles post-LOE.
Brand ManagerField Sales Representative
Worked on TAMBOCOR at Alvogen? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.